Vigil Neuroscience, Inc. (VIGL)
Vigil Neuroscience, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Watertown, MA, US. The stock last traded at $8.05, up 0.00% on the session, giving a market capitalisation of $375.7M. On trailing twelve-month figures it carries a trailing P/E of -7.67, a net margin of 0.0%. Its beta of 3.34 implies it has historically moved more than the broad market.
Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.
Vigil Neuroscience, Inc. is most often compared with the following Healthcare names: